|
Bonvalot et al. [12]
|
112
|
46/66
|
112/0
|
6
|
76
|
11
|
3 (27%)
|
NR
|
NR
|
NR
|
NR
|
|
Fiore et al. [3]
|
142
|
48/94
|
74/68
|
6
|
33
|
83
|
33 (40%)
|
47 (57%)
|
3 (4%)
|
47% PFS at 60 months
|
No difference in PFS between observation and chemotherapy
|
|
Barbier et al. [13]
|
26
|
0/26
|
11/15
|
NR
|
22
|
26
|
1 (4%)
|
24 (92%)
|
1 (4%)
|
Median time to stabilization 14 months
|
NR
|
|
Salas et al. [14]
|
426
|
120/306
|
426/0
|
7
|
52
|
27
|
6 (22%)
|
16 (59%)
|
5 (19%)
|
Median delay to progression 19.7 months
|
NR
|
|
Briand et al. [15]
|
73
|
0/73
|
31/24
|
7.5
|
73
|
55
|
5 (9%)
|
42 (76%)
|
5 (9%)
|
Median time to stabilization 9 months
|
NR
|
|
Huang et al. [16]
|
214
|
104/100
|
153/61
|
5.5
|
45
|
20
|
4 (20%)
|
14 (70%)
|
2 (10%)
|
Median delay to progression 15.3 months
|
NR
|
|
Park et al. [17]
|
47
|
7/40
|
47/0
|
8
|
36
|
20
|
1 (5%)
|
18 (90%)
|
1 (5%)
|
92% PFS at 36 months
|
Superior PFS in observation compared to surgery
|
|
Burtenshaw et al. [18]
|
213
|
213/0
|
195/18
|
6
|
54
|
63
|
4 (6%)
|
36 (57%)
|
23 (37%)
|
NR
|
NR
|
|
Penel et al. [19]
|
771
|
374/397
|
NR
|
5.7
|
32
|
388
|
117 (30%)
|
NR
|
NR
|
58% PFS at 24 months
|
No difference in PFS between observation and surgery
|
|
Orbach et al. [20]
|
154
|
NR
|
NR
|
NR
|
21
|
54
|
32 (59%)
|
9 (17%)
|
4 (7%)
|
NR
|
No difference in PFS between observation, surgery and chemotherapy
|
|
Cassidy et al. [21]
|
160
|
84/76
|
NR
|
4.7
|
15
|
37
|
10 (27%)
|
NR
|
NR
|
NR
|
NR
|
|
van Broekhoven et al. [22]
|
91
|
25/66
|
NR
|
NR
|
16
|
37
|
5 (14%)
|
25 (68%)
|
2 (5%)
|
NR
|
NR
|
|
van Houdt et al. [23]
|
168
|
76/92
|
NR
|
5.9
|
41
|
168
|
60 (36%)
|
60 (36%)
|
45 (27%)
|
NR
|
NR
|
|
Turner et al. [24]
|
103
|
42/61
|
NR
|
6.2
|
35
|
50
|
21 (42%)
|
29 (58%)
|
0
|
38% PFS at 36 months
|
NR
|
|
de Bruyns et al. [25]
|
227
|
89/138
|
NR
|
5.4
|
77
|
55
|
13 (24%)
|
20 (36%)
|
22 (40%)
|
71% PFS at 24 months
|
NR
|
